Q1 Earnings Estimate for CRBP Issued By HC Wainwright

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Corbus Pharmaceuticals in a report issued on Thursday, November 13th. HC Wainwright analyst A. Maldonado forecasts that the biopharmaceutical company will post earnings per share of ($1.31) for the quarter. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Corbus Pharmaceuticals’ Q2 2026 earnings at ($1.32) EPS, Q3 2026 earnings at ($1.34) EPS and Q4 2026 earnings at ($1.37) EPS.

A number of other equities analysts have also recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a report on Wednesday, October 8th. Piper Sandler reiterated an “overweight” rating and set a $51.00 target price on shares of Corbus Pharmaceuticals in a research note on Monday, October 20th. B. Riley raised Corbus Pharmaceuticals to a “strong-buy” rating and set a $28.00 target price for the company in a research report on Wednesday, July 30th. Royal Bank Of Canada cut their price target on Corbus Pharmaceuticals from $55.00 to $53.00 and set an “outperform” rating for the company in a research note on Thursday. Finally, Wedbush boosted their price target on shares of Corbus Pharmaceuticals from $31.00 to $38.00 and gave the stock an “outperform” rating in a research report on Monday, October 20th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Corbus Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $44.38.

Corbus Pharmaceuticals Stock Performance

NASDAQ:CRBP opened at $11.07 on Friday. Corbus Pharmaceuticals has a 52-week low of $4.64 and a 52-week high of $20.56. The firm has a market cap of $135.66 million, a price-to-earnings ratio of -2.33 and a beta of 2.69. The business’s fifty day moving average is $13.36 and its 200 day moving average is $10.14.

Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its quarterly earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($1.90) EPS for the quarter, missing analysts’ consensus estimates of ($1.80) by ($0.10).

Institutional Investors Weigh In On Corbus Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of CRBP. Nuveen LLC acquired a new stake in Corbus Pharmaceuticals in the first quarter valued at $243,000. AlphaQuest LLC acquired a new stake in shares of Corbus Pharmaceuticals in the first quarter worth $299,000. Stonepine Capital Management LLC purchased a new position in Corbus Pharmaceuticals in the 1st quarter worth approximately $186,000. Comerica Bank lifted its position in shares of Corbus Pharmaceuticals by 20,000,000.0% during the first quarter. Comerica Bank now owns 200,001 shares of the biopharmaceutical company’s stock worth $1,062,000 after purchasing an additional 200,000 shares in the last quarter. Finally, Velan Capital Investment Management LP grew its stake in Corbus Pharmaceuticals by 4.1% during the 1st quarter. Velan Capital Investment Management LP now owns 59,000 shares of the biopharmaceutical company’s stock valued at $313,000 after purchasing an additional 2,300 shares in the last quarter. 64.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Corbus Pharmaceuticals news, CEO Yuval Cohen sold 18,660 shares of Corbus Pharmaceuticals stock in a transaction on Friday, October 24th. The shares were sold at an average price of $17.01, for a total value of $317,406.60. Following the completion of the transaction, the chief executive officer owned 138,187 shares of the company’s stock, valued at approximately $2,350,560.87. The trade was a 11.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Sean F. Moran sold 12,981 shares of the stock in a transaction that occurred on Friday, October 24th. The stock was sold at an average price of $17.02, for a total value of $220,936.62. Following the transaction, the chief financial officer owned 73,313 shares in the company, valued at $1,247,787.26. This represents a 15.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 41,674 shares of company stock valued at $713,870 over the last three months. 3.60% of the stock is currently owned by corporate insiders.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.